Clinica e Investigacion en Arteriosclerosis最新文献

{"title":"Myeloproliferative neoplasms: A model of the journey from clonal hematopoiesis to cardiovascular disease and cancer.","authors":"Santiago Redondo","doi":"10.1016/j.arteri.2025.500767","DOIUrl":"https://doi.org/10.1016/j.arteri.2025.500767","url":null,"abstract":"<p><p>In the last decade, the coming of next-generation sequencing and its application to large human populations is breaking the barrier between inflammation and cancer. Indeed, acquired mutations in key genes that regulate hematopoiesis and thus confer a selective advantage in the proliferation of hematopoietic progenitors have established the concept of clonal hematopoiesis of indeterminate potential or CHIP. A growing body of clinical and experimental evidence is highlighting the link between CHIP and adverse outcomes, in particular atherosclerotic cardiovascular disease and cancer. The apparent surprise about how these two different entities share common mechanisms can be explained by myeloproliferation and inflammation. These mechanisms are involved not only in the development of myeloid tumors but also in atherogenesis. Myeloproliferative neoplasms or MPN are a type of myeloid tumors where thrombotic risk is increased not only by higher blood counts but also by means of an accelerated atherosclerosis. Therefore, myeloproliferative neoplasms are a model of the link between clonal hematopoiesis and atherosclerotic cardiovascular disease. The concept of CHIP has important clinical applications. A deeper understanding of these mechanisms may pave the way for the future early diagnosis and potential pre-emptive treatments of these two major causes of death.</p>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":" ","pages":"500767"},"PeriodicalIF":1.9,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Environmental pollution and cardiovascular health. Challenges and new perspectives.","authors":"Francisco Gomez-Delgado, Manuel Raya-Cruz, Juan L Romero-Cabrera, Pablo Perez-Martinez","doi":"10.1016/j.arteri.2025.500802","DOIUrl":"https://doi.org/10.1016/j.arteri.2025.500802","url":null,"abstract":"<p><p>Environmental pollution is a key factor in cardiovascular disease (CVD) development. Several evidences support its impact at the pathophysiology of arteriosclerosis, highlighting the role of the \"exposome\", a concept that encompasses all environmental factors such as air pollution, water pollution, climate change and noise and light pollution. These factors are associated with an increased risk of ischemic heart disease (IHD), stroke, high blood pressure (HBP), heart failure (HF) and atrial fibrillation (AF). Currently, air pollution is the main environmental factor related to CVD. Components such as particulates matter (PM_0.1, PM_2.5, PM₁₀), sulfur dioxide (SO₂), nitrogen oxide and dioxide (NO_x), carbon monoxide (CO) and ozone (O₃) have a high capacity to penetrate the body and trigger both local and systemic inflammatory processes. These effects promote a proinflammatory, procoagulant state and an increase in oxidative stress. Similarly, aquatic pollution exposes the body to pollutants such as heavy metals, pesticides and microplastics, both through direct contact and via the food chain, thus contributing to the phenomena mentioned above. On the other hand, factors such as noise and light pollution, together with effects caused from climate change (extreme temperatures, wildfires, desertification, among others), have been closely linked to pathophysiological processes that favour the development and progression of atherosclerosis. These mechanisms include sympathetic nervous system (SNS) activation, stress hormones release such as cortisol and catecholamines, as well as chronodisruption. This review analyses the role of factors related to the exposome (air pollution, water pollution, noise and light pollution and phenomena associated with climate change) in atherosclerosis progression, as well as their involvement in the incidence, prevalence and prognosis of CVD. Physicians should promote awareness of environmental pollution impact on cardiovascular health, integrating the assessment of environmental factors into their clinical practice, advocating for sustainable policies to prevent diseases and protect present and future health.</p>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":" ","pages":"500802"},"PeriodicalIF":1.9,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between sociodemographic variables, lifestyle factors, and stress with lipoprotein ratio values.","authors":"Ángel Arturo López-González, José Ignacio Ramírez-Manent, Emilio Martínez-Almoyna Rifá, Hernán Paublini Oliveira, Cristina Martorell Sánchez, Pedro Juan Tárraga López","doi":"10.1016/j.arteri.2025.500803","DOIUrl":"https://doi.org/10.1016/j.arteri.2025.500803","url":null,"abstract":"<p><strong>Introduction: </strong>Atherosclerosis is a multifactorial process underlying major cardiovascular diseases (CVDs). Among the associated risk factors, lipoprotein ratios have been identified as key indicators of atherogenic risk. However, the influence of sociodemographic variables, lifestyle factors, and stress levels on lipoprotein ratios remains underexplored.</p><p><strong>Objective: </strong>To analyze the relationship between sociodemographic variables, healthy lifestyle habits, and stress levels with lipoprotein ratios and atherogenic risk in a large cohort of Spanish workers.</p><p><strong>Materials and methods: </strong>A cross-sectional study was conducted in 24,244 Spanish workers. The association between age, gender, socioeconomic status, tobacco and alcohol consumption, physical activity, adherence to the Mediterranean diet, and stress levels with atherogenic risk scales, including atherogenic dyslipidemia (AD) and atherogenic índices, was evaluated.</p><p><strong>Results: </strong>A significant association was found between all analyzed variables and lipoprotein ratios. The strongest associations were observed with age and gender, followed by occupational status, tobacco and alcohol consumption, physical activity, diet, and stress levels. Men exhibited a higher atherogenic risk compared to women (OR 2.36; 95% CI 2.18-2.55). The risk increased significantly with age, peaking in the 50-69 age group (OR 5.00; 95% CI 3.70-6.31). Manual workers had a higher prevalence of atherogenic dyslipidemia compared to non-manual workers (OR 1.35; 95% CI 1.27-1.41). Furthermore, smoking (OR 1.84; 95% CI 1.71-1.97) and alcohol consumption (OR 1.45; 95% CI 1.36-1.55), physical inactivity (OR 1.90; 95% CI 1.76-2.05), and low adherence to the Mediterranean diet (OR 1.72; 95% CI 1.60-1.84) were associated with higher atherogenic index values.</p><p><strong>Conclusions: </strong>The presence of an adverse lipoprotein profile is strongly influenced by sociodemographic factors, lifestyle habits, and stress. Identifying these determinants may enable the implementation of preventive strategies aimed at reducing atherogenic risk and improving cardiovascular health in working populations.</p>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":" ","pages":"500803"},"PeriodicalIF":1.9,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Eficiencia de las combinaciones a dosis fija de estatina y ezetimiba en el tratamiento de la hipercolesterolemia","authors":"Carlos Guijarro ,&nbsp;Angel Diaz ,&nbsp;Eva Moreno ,&nbsp;Paula Gamonal ,&nbsp;Maria Soler ,&nbsp;Neus Vidal-Vilar ,&nbsp;Maria Rosa Fernandez","doi":"10.1016/j.arteri.2024.500753","DOIUrl":"10.1016/j.arteri.2024.500753","url":null,"abstract":"<div><h3>Objective</h3><div>To estimate the clinical and economic benefits derived from increasing the use of fixed-dose combinations of high-intensity statins and ezetimibe in patients at high/very high cardiovascular risk, from the perspective of the Spanish National Health System (SNS).</div></div><div><h3>Methods</h3><div>A baseline scenario (current market shares) was compared with scenarios that increased the use of fixed-dose combinations (alternative: 30% increase; optimized: 69% increase). The potential annual increase in the number of controlled patients, cardiovascular events avoided and the associated savings in direct medical costs were estimated, including the cost of pharmacological treatment, follow-up, and managing cardiovascular events over a three-year time horizon.</div></div><div><h3>Results</h3><div>Over the three years of the study, the baseline scenario estimated a total of 1,552,686 controlled patients and 39,449 cardiovascular events, with a total cost to the SNS of €1,841,057,122. In the alternative scenario, controlled patients would increase by 36.1%, and 139 cardiovascular events would be avoided, resulting in savings for the SNS of €36,116,631. In the optimized scenario, there would be a 64% increase in controlled patients and 250<!--> <!-->cardiovascular events would be avoided, leading to savings of €56,415,300 for the SNS.</div></div><div><h3>Conclusion</h3><div>Increased use of high-intensity statin and ezetimibe fixed-dose combinations in patients with high/very high cardiovascular risk may increase the number of controlled patients, reduce cardiovascular events and produce economic savings from an SNS perspective.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 3","pages":"Article 500753"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142928225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma expression of a microRNA panel is differentially associated with 1H-NMR lipoprotein profile in rheumatoid arthritis patients","authors":"Dídac Llop ,&nbsp;Silvia Paredes ,&nbsp;Roser Rosales ,&nbsp;Josep Ribalta ,&nbsp;Joan-Carles Vallvé","doi":"10.1016/j.arteri.2025.500759","DOIUrl":"10.1016/j.arteri.2025.500759","url":null,"abstract":"<div><h3>Introduction</h3><div>Rheumatoid arthritis (RA) is an autoimmune and inflammatory disorder that leads to cartilage and bone deterioration. This inflammatory activity causes extra-articular manifestations, including the acceleration of the atherosclerotic process. However, the exact causes of this accelerated process are under investigation. In this study, we compared the advanced lipid profile between patients with RA, patients with metabolic disorders, and controls. We also explored how microRNAs previously associated with subclinical atherosclerosis in RA are linked to these lipid subfractions in RA.</div></div><div><h3>Methods</h3><div>The study included 219 patients with RA, 82 with metabolic disorders and 64 controls. Clinical evaluations were performed, and blood samples were collected. Quantification of microRNAs (Let7a, 24, 96, 103, 125a, 125b, 132, 146, 191, 223, 425, 451) and measurement of the advanced lipid profile using nuclear magnetic resonance (NMR) were carried out. Kruskal–Wallis tests and multivariate linear models were applied.</div></div><div><h3>Results</h3><div>Patients with RA exhibited elevated total, large, medium, and small VLDL particles compared to controls. Their LDL subfractions were decreased compared to patients with metabolic disorders, with differences with controls. Patients with RA had fewer and smaller HDL particles than both groups. MicroRNA-125a was associated with VLDL subfractions and small LDL particles. Other microRNAs (96, 132, 191, 451) showed associations with certain LDL subfractions.</div></div><div><h3>Conclusions</h3><div>In patients with RA, elevated levels of VLDL particles have been observed, while LDL levels remain similar to controls. The notable association of microRNA-125a with the metabolism of both VLDL and LDL in RA patients suggests its involvement in lipid regulation. This could point to microRNA-125a as a promising therapeutic target to address the increased cardiovascular risks of RA.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 3","pages":"Article 500759"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¿Cómo alcanzar los objetivos en colesterol LDL con los criterios de financiación de los nuevos fármacos hipolipemiantes?","authors":"Antón González-Guerrero ,&nbsp;Elisenda Climent ,&nbsp;David Benaiges ,&nbsp;Juan PedroBotet","doi":"10.1016/j.arteri.2024.500752","DOIUrl":"10.1016/j.arteri.2024.500752","url":null,"abstract":"<div><div>Given the apparent inconsistency of having potent lipid-lowering drugs and the unacceptable rate of achievement of therapeutic goals in LDL cholesterol, it is imperative to define new strategies. In this regard, it is appropriate to detail the key points in planning to start lipid-lowering therapy, emphasizing relevant clinical aspects such as the considerable individual variability in the response to statin therapy, positioning in relation to high-potency statins versus statin<!--> <!-->+<!--> <!-->ezetimibe combination therapy, and the order of choice of lipid-lowering drugs in the therapeutic strategy. An algorithm is then proposed that ensures a personalized approach to lipid-lowering drug treatment in patients with cardiovascular disease and/or familial hypercholesterolemia with the aim of achieving the therapeutic goal in the shortest possible time, taking into account the patient's previous treatment, the funding criteria for new drugs, and the individualized goal of LDL cholesterol reduction.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 3","pages":"Article 500752"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142910904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"La complejidad del riesgo cardiovascular en las mujeres. Revisión descriptiva","authors":"J. Ildefonzo Arocha Rodulfo ,&nbsp;Gestne Aure Fariñez","doi":"10.1016/j.arteri.2024.08.005","DOIUrl":"10.1016/j.arteri.2024.08.005","url":null,"abstract":"<div><h3>Objectives</h3><div>Cardiovascular diseases (CVD) are the greatest threat to the health of women and is the leading cause of death amongst women globally; however, cardiovascular disease in women remains understudied, under-recognized, underdiagnosed, and undertreated. The aim of this descriptive review is to summarize the existing problem and to identify the knowledge gaps in cardiovascular disease research, prevention, treatment, and access to care for women.</div></div><div><h3>Material and methods</h3><div>This is a descriptive review of the literature based on numerous articles published in peer-reviewed journals since the beginning of this century related to the spectrum of cardiovascular disease in women.</div></div><div><h3>Results</h3><div>There are several obstacles to improve cardiovascular disease outcomes in women. One of them is the lack of reliable, effective screening modalities since her participation in clinical trial is quite low. Other concern is the complexity of the female organism with several hormonal changes during her life and the hemodynamics stress during pregnancy. Moreover, in the last stage of their life several cardiometabolic risk factor may appear, most of them not recognized by the health team in primary care attention.</div></div><div><h3>Discussion</h3><div>Effective strategies are required to address inequalities in the diagnosis, treatment and prevention of heart disease in women; to advance innovative solutions for early detection and oriented management; to clarify the underlying biological mechanisms that contribute to sex-specific differences in outcomes; and finally, reduce the global burden of cardiovascular disease in women.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 3","pages":"Article 100736"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asociación entre variables sociodemográficas, hábitos saludables y estrés con diabesidad","authors":"Ángel Arturo López-González ,&nbsp;Emilio Martínez-Almoyna Rifá ,&nbsp;Hernán Paublini Oliveira ,&nbsp;Cristina Martorell Sánchez ,&nbsp;Pedro Juan Tárraga López ,&nbsp;José Ignacio Ramírez-Manent","doi":"10.1016/j.arteri.2024.500754","DOIUrl":"10.1016/j.arteri.2024.500754","url":null,"abstract":"<div><h3>Introduction</h3><div>Diabesity is a pathological condition that combines obesity and type 2 diabetes in the same individual. Due to the current rise in both conditions, the prevalence of diabesity is increasing worldwide. Its etiology is known to be multifactorial; therefore, the aim of this study is to understand how diabesity is associated with various sociodemographic variables, healthy habits, and stress.</div></div><div><h3>Materials and Methods</h3><div>A descriptive, cross-sectional study was conducted on 24,224 Spanish workers to evaluate the association between diabesity and various factors such as age, gender, socioeconomic status, smoking, alcohol consumption, physical activity, adherence to the Mediterranean diet, and stress. The criteria used to define diabesity included body mass index (BMI), body fat (BF), and visceral fat (VF).</div></div><div><h3>Results</h3><div>All the aforementioned variables were found to be associated with diabesity. The highest odds ratios (OR) were observed for age, with values ranging from 5.57 (95% CI: 4.48-6.67) when BF was used as the diabesity criterion to 6.89 (95% CI: 5.60-8.19) when VF was the criterion. Similarly, elevated ORs were observed for male gender, with ORs of 6.77 (95% CI: 5.31-8.24) for VF and 3.34 (95% CI: 2.77-3.94) for BF.</div></div><div><h3>Conclusions</h3><div>In our study, the profile of a person at highest risk of diabesity is a man over 50 years old from a lower socioeconomic status, who is a smoker, regular alcohol consumer, sedentary, with low adherence to the Mediterranean diet, and experiencing high stress levels.</div></div>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 3","pages":"Article 500754"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143013852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroARNs asociados a partículas lipídicas con potencial para prevenir o reducir el desarrollo de arteriosclerosis en pacientes con Artritis Reumatoide","authors":"Oriol Alberto Rangel-Zúñiga","doi":"10.1016/j.arteri.2025.500825","DOIUrl":"10.1016/j.arteri.2025.500825","url":null,"abstract":"","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":"37 3","pages":"Article 500825"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144185430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the link between fibrates therapy and diabetes mellitus following primary acute pancreatitis with hypertriglyceridemia.","authors":"Jiali Xu, Nana Deng, Zhouyue Zhang, Mingming Deng, Gang Luo","doi":"10.1016/j.arteri.2025.500800","DOIUrl":"https://doi.org/10.1016/j.arteri.2025.500800","url":null,"abstract":"<p><strong>Objective: </strong>Post-acute pancreatitis diabetes mellitus (PPDM-A) is a type of diabetes linked to pancreatic exocrine dysfunction, which increases the risk of pancreatic cancer and mortality. Hyperlipidemia, or high blood lipid levels, is the third leading cause of acute pancreatitis (AP) and is associated with a higher diabetes risk. However, the link between lipid-lowering treatments and PPDM-A is unclear. This study aims to explore this relationship.</p><p><strong>Methods: </strong>A cohort of 223 patients diagnosed with AP and hyperlipidemia was categorized into PPDM-A and non-PPDM-A groups. Binary logistic regression was utilized to analyze the correlation between fibrate therapy and PPDM-A incidence. Mendelian randomization (MR) was used to determine whether there was a causal relationship between triglyceride levels and diabetes.</p><p><strong>Results: </strong>Elevated blood glucose levels (GLU) (OR=1.360, p<0.001), female (OR=0.091, p=0.030), severity of AP [moderately severe AP (MASP) (OR=5.585, p=0.019)], recurrent acute pancreatitis (RAP) (OR=6.399, p=0.007), and fibrate use (OR=0.109, p=0.001) emerged as independent influencing factors of PPDM-A. MR evidence suggests a causal relationship between triglyceride levels and diabetes risk (OR=1.088, p<0.001), with a two-step MR showing that pancreatitis partially mediates this effect with a mediated proportion of 1.55% (p=0.048).</p><p><strong>Conclusion: </strong>Fibrates demonstrate the potential to lower the risk of PPDM-A among individuals with AP and hypertriglyceridemia. Furthermore, the effect of triglyceride levels on diabetes risk was partly mediated by pancreatitis.</p>","PeriodicalId":45230,"journal":{"name":"Clinica e Investigacion en Arteriosclerosis","volume":" ","pages":"500800"},"PeriodicalIF":1.9,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}